The article focuses on the pivotal trial for Gelesis100, a superabsorbent hydrogel, published in this issue. Around 436 participants were randomized to Gelesis100 or placebo in the Gelesis Loss of Weight (GLOW) trial, which found that the placebo was well tolerated among participants, with minimal adverse events.